Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., et al. (2012). Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150(6), 1121–1134. https://doi.org/10.1016/j.cell.2012.08.024

Article  CAS  PubMed  PubMed Central  Google Scholar 

To, K. K. W., Fong, W., & Cho, W. C. S. (2021). Immunotherapy in treating EGFR-mutant lung cancer: Current challenges and new strategies. Frontiers in Oncology, 11, 635007. https://doi.org/10.3389/fonc.2021.635007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wee, P., & Wang, Z. (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel), 9(5), 52. https://doi.org/10.3390/cancers9050052

Article  CAS  PubMed  Google Scholar 

Mitsudomi, T., & Yatabe, Y. (2007). Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 98(12), 1817–1824. https://doi.org/10.1111/j.1349-7006.2007.00607.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borgeaud, M., Parikh, K., Banna, G. L., Kim, F., Olivier, T., Le, X., et al. (2024). Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review. Journal of Thoracic Oncology, 19(7), 973–983. https://doi.org/10.1016/j.jtho.2024.03.016

Article  CAS  PubMed  Google Scholar 

Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D’Angelo, S. P., Paik, P. K., et al. (2012). Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical Cancer Research, 18(22), 6169–6177. https://doi.org/10.1158/1078-0432.CCR-11-3265

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karachaliou, N., Fernandez-Bruno, M., Bracht, J. W. P., & Rosell, R. (2019). EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 8(Suppl 1), S23–S47. https://doi.org/10.21037/tcr.2018.10.06

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., et al. (2017). Osimertinib or platinum-pemetrexed in EGFR T790M-positive Lung cancer. New England Journal of Medicine, 376(7), 629–640. https://doi.org/10.1056/NEJMoa1612674

Article  CAS  PubMed  Google Scholar 

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., et al. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137

Article  CAS  PubMed  Google Scholar 

Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019). Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer, 121(9), 725–737. https://doi.org/10.1038/s41416-019-0573-8

Article  PubMed  PubMed Central  Google Scholar 

Chiu, C. H., Yang, C. T., Shih, J. Y., Huang, M. S., Su, W. C., Lai, R. S., et al. (2015). Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. Journal of Thoracic Oncology, 10(5), 793–799. https://doi.org/10.1097/JTO.0000000000000504

Article  CAS  PubMed  Google Scholar 

Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., et al. (2014). Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. Journal of Thoracic Oncology, 9(2), 189–194. https://doi.org/10.1097/JTO.0000000000000048

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen, Y. C., Tseng, G. C., Tu, C. Y., Chen, W. C., Liao, W. C., Chen, W. C., et al. (2017). Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer, 110, 56–62. https://doi.org/10.1016/j.lungcan.2017.06.007

Article  PubMed  Google Scholar 

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., et al. (2020). Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). Journal of Clinical Oncology, 38(5), 488–495. https://doi.org/10.1200/JCO.19.00931

Article  CAS  PubMed  Google Scholar 

Okuma, Y., Kubota, K., Shimokawa, M., Hashimoto, K., Kawashima, Y., Sakamoto, T., et al. (2024). First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: The UNICORN phase 2 nonrandomized clinical trial. JAMA Oncology, 10(1), 43–51. https://doi.org/10.1001/jamaoncol.2023.5013

Article  PubMed  Google Scholar 

Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: From undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 6(1), 386. https://doi.org/10.1038/s41392-021-00780-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016). Prognostic and predictive value in KRAS in non-small-cell lung cancer: A review. JAMA Oncology, 2(6), 805–812. https://doi.org/10.1001/jamaoncol.2016.0405

Article  PubMed  Google Scholar 

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007). Lung cancer in never smokers–a different disease. Nature Reviews Cancer, 7(10), 778–790. https://doi.org/10.1038/nrc2190

Article  CAS  PubMed  Google Scholar 

McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., et al. (2016). Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A, 113(42), E6409–E6417. https://doi.org/10.1073/pnas.1613601113

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., et al. (2022). Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol, 6(1), 91. https://doi.org/10.1038/s41698-022-00334-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., et al. (2021). Characterization of KRAS mutation subtypes in non-small cell lung cancer. Molecular Cancer Therapeutics, 20(12), 2577–2584. https://doi.org/10.1158/1535-7163.MCT-21-0201

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., et al. (2022). Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer. Annals of Oncology, 33(10), 1029–1040. https://doi.org/10.1016/j.annonc.2022.07.005

Article  CAS  PubMed  Google Scholar 

Liu, P., Wang, Y., & Li, X. (2019). Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B, 9(5), 871–879. https://doi.org/10.1016/j.apsb.2019.03.002

Article  PubMed  PubMed Central  Google Scholar 

Mao, C., Qiu, L. X., Liao, R. Y., Du, F. B., Ding, H., Yang, W. C., et al. (2010). KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer, 69(3), 272–278. https://doi.org/10.1016/j.lungcan.2009.11.020

Article  PubMed  Google Scholar 

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine, 384(25), 2371–2381. https://doi.org/10.1056/NEJMoa2103695

Article  CAS  PubMed  Google Scholar 

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., et al. (2020). The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discovery, 10(1), 54–71. https://doi.org/10.1158/2159-8290.CD-19-1167

Article